| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
|
Stopfer, Peter
|
|
2011
|
69 |
4 |
p. 1051-1061
|
artikel
|
| 2 |
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model
|
Luo, Yanping
|
|
2011
|
69 |
4 |
p. 911-921
|
artikel
|
| 3 |
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423
|
Dorr, Robert T.
|
|
2011
|
69 |
4 |
p. 1039-1049
|
artikel
|
| 4 |
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
|
Padda, Sukhmani K.
|
|
2011
|
69 |
4 |
p. 1013-1020
|
artikel
|
| 5 |
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
|
Campone, M.
|
|
2011
|
69 |
4 |
p. 871-879
|
artikel
|
| 6 |
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
|
Iyer, Gopa
|
|
2011
|
69 |
4 |
p. 1089-1097
|
artikel
|
| 7 |
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
|
Ning, Zhi-Qiang
|
|
2011
|
69 |
4 |
p. 901-909
|
artikel
|
| 8 |
CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice
|
Pei, Ke-Ling
|
|
2011
|
69 |
4 |
p. 1029-1038
|
artikel
|
| 9 |
Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation
|
Sprio, Andrea Elio
|
|
2011
|
69 |
4 |
p. 983-989
|
artikel
|
| 10 |
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
|
Cauchi, C.
|
|
2011
|
69 |
4 |
p. 977-982
|
artikel
|
| 11 |
Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo
|
Fang, Lin
|
|
2011
|
69 |
4 |
p. 1079-1087
|
artikel
|
| 12 |
Going past the data for temozolomide
|
Villano, J. Lee
|
|
2011
|
69 |
4 |
p. 1113-1115
|
artikel
|
| 13 |
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells
|
Mamidipudi, Vidya
|
|
2011
|
69 |
4 |
p. 965-976
|
artikel
|
| 14 |
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients
|
Takahashi, Naoto
|
|
2011
|
69 |
4 |
p. 999-1004
|
artikel
|
| 15 |
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation
|
Lima-Júnior, Roberto César P.
|
|
2011
|
69 |
4 |
p. 931-942
|
artikel
|
| 16 |
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
|
Satoh, Taroh
|
|
2011
|
69 |
4 |
p. 949-955
|
artikel
|
| 17 |
Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer
|
Makino, Yoshinori
|
|
2011
|
69 |
4 |
p. 861-869
|
artikel
|
| 18 |
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
|
Morizane, Chigusa
|
|
2011
|
69 |
4 |
p. 957-964
|
artikel
|
| 19 |
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer
|
Wada, M.
|
|
2011
|
69 |
4 |
p. 1005-1011
|
artikel
|
| 20 |
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
|
Seki, Yoshitaka
|
|
2011
|
69 |
4 |
p. 1099-1105
|
artikel
|
| 21 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
|
Murakami, H.
|
|
2011
|
69 |
4 |
p. 891-899
|
artikel
|
| 22 |
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates
|
Muscal, Jodi A.
|
|
2011
|
69 |
4 |
p. 943-947
|
artikel
|
| 23 |
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
|
Kamath, Amrita V.
|
|
2011
|
69 |
4 |
p. 1063-1069
|
artikel
|
| 24 |
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
|
Kamath, Amrita V.
|
|
2011
|
69 |
4 |
p. 1071-1078
|
artikel
|
| 25 |
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients
|
Nakai, Katsuya
|
|
2011
|
69 |
4 |
p. 923-930
|
artikel
|
| 26 |
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
|
Reardon, David A.
|
|
2011
|
69 |
4 |
p. 849-860
|
artikel
|
| 27 |
The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
|
Bello, Carlo L.
|
|
2011
|
69 |
4 |
p. 991-997
|
artikel
|
| 28 |
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
|
Hansson, Emma K.
|
|
2011
|
69 |
4 |
p. 881-890
|
artikel
|
| 29 |
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
|
DuBois, Steven G.
|
|
2011
|
69 |
4 |
p. 1021-1027
|
artikel
|
| 30 |
Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity
|
Cao, Shousong
|
|
2012
|
69 |
4 |
p. 1107-1111
|
artikel
|
Tijdschrift beschrijving